SYDNEY,Sept. 13,2024 --Aurora Biosynthetics,a pioneering advanced RNA therapeutics manufacturing company,announced its official launch. This heralds a new era in RNA therapeutics manufacturing across the Asia-Pacific region. Aurora Biosynthetics is poised to meet the surging demand for advanced RNA-based therapies by providing a complete end-to-end solution for Good Manufacturing Practice (GMP) production of plasmid DNA (pDNA),messenger RNA (mRNA),and lipid nanoparticles (LNP).

Strategic Collaboration with the NSW Government,RNA Australia and Myeloid Therapeutics

Aurora Biosynthetics reflects a strategically important,public-private partnership between the New South Wales (NSW) Government,RNA Australia and Myeloid Therapeutics,a leader in RNA immunotherapies. This collaboration combines cutting-edge RNA manufacturing capabilities with strong support from the NSW Government,supporting Aurora's rapid build,scale-up and robust entry into the global RNA manufacturing market.

The NSW Government committed AU$200 million in support of the RNA ecosystem in Australia,and it accepted the construction costs associated with building this state-of-the-art manufacturing facility. The facility is co-located on Macquarie University,in Sydney,NSW,in a location that uniquely positions Australia to make gains across the RNA field,including fostering collaboration with leading academic researchers and ensuring access to a highly skilled workforce.

Comprehensive RNA Manufacturing Capabilities

Aurora Biosynthetics is uniquely positioned to provide a fully-integrated RNA manufacturing solution that will enable product creation,development and commercialization,including:

GMP Plasmid Production: Essential for supporting cell and gene therapies,as well as mRNA production

GMP RNA Production: Specializing in the production of RNA

GMP Lipid Nanoparticle Production: Offering LNP encapsulation for mRNA and other active pharmaceutical ingredients (APIs) using the latest technologies

Fill-Finish Services: Providing final formulation and fill-finish capabilities for clinical trial and commercial use

This comprehensive suite of services enables Aurora to offer a streamlined,one-stop solution that reduces complexity and accelerates time-to-market for its collaborators and clients.

Vision for the Future

Aurora will address the growing market need for high-quality RNA therapeutics manufacturing,within the rapidly expanding field of cell and gene therapies. With a projected compound annual growth rate (CAGR) of over 20% for cell and gene therapies,Aurora's heritage keeps it well-positioned to become the GMP manufacturer of choice for the Asia-Pacific region and beyond.

Aurora's leadership team combines deep expertise in RNA technology development and manufacturing. The team is focused on scaling the business to attain a compelling financial foundation.

Economic Impact and Support for Innovation

Clients utilizing Aurora Biosynthetics services are also set to benefit from Australia's R&D tax credit,which offers a 43% cash back on R&D spend,further incentivizing RNA client customers to bring their programs to Australia. This,combined with the strong support from the NSW Government,positions Aurora as a critical player in the global RNA manufacturing landscape.

About Aurora Biosynthetics

Aurora Biosynthetics is a cutting-edge RNA manufacturing company dedicated to providing an end-to-end solution for the production of pDNA,mRNA,and LNPs. Based in Sydney,Australia,Aurora leverages strategic partnerships and public-private collaboration to meet the growing global demand for RNA-based therapies. As a subsidiary of Myeloid Therapeutics,Aurora is committed to advancing the field of RNA therapeutics and delivering exceptional value to its customers.

For more information,please visit www.aurorabiosynthetics.com or contact us at info@aurorabiosynthetics.com.

Logo - /up/2024/0913/24091320060184742843.jpg